We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Dare Bioscience Inc (DARE) USD0.0001

Sell:$0.56 Buy:$0.58 Change: $0.0507 (10.17%)
Market closed |  Prices as at close on 27 March 2024 | Switch to live prices |
Sell:$0.56
Buy:$0.58
Change: $0.0507 (10.17%)
Market closed |  Prices as at close on 27 March 2024 | Switch to live prices |
Sell:$0.56
Buy:$0.58
Change: $0.0507 (10.17%)
Market closed |  Prices as at close on 27 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Dare Bioscience, Inc. is a biopharmaceutical company. The Company is engaged in identifying, developing, and marketing a portfolio of differentiated therapies that prioritize women's health and well-being, primarily in the areas of contraception, vaginal health, reproductive health, menopause, sexual health and fertility. Its first product, XACIATO, is a clindamycin phosphate vaginal gel used for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its pipeline includes various other clinical-stage programs, such as Ovaprene, Sildenafil Cream 3.6%, DARE-HRT1, DARE-VVA1, DARE-FRT1 and DARE-PTB1. Its pre-clinical-stage programs include DARE-LARC1, DARE-GML, DARE-LBT, and DARE-RH1. Ovaprene is an investigational hormone-free monthly intravaginal contraceptive. Sildenafil Cream 3.6% is a proprietary cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder (FSAD).

Contact details

Address:
3655 Nobel Dr Ste 260
SAN DIEGO
92122-1050
United States
Telephone:
+1 (858) 9267655
Website:
https://www.darebioscience.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
DARE
ISIN:
US23666P1012
Market cap:
$54.11 million
Shares in issue:
98.56 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Sabrina Johnson
    President, Chief Executive Officer, Principal Financial Officer, Company Secretary, Director
  • John Fair
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.